VNTH Nano Mobile Healthcare Inc (PK)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14C INFORMATION

 

Information Statement Pursuant to Section 14(c)

of the Securities Exchange Act of 1934

(Amendment No. 1)

 

Check the appropriate box:

 

[X]	Preliminary Information Statement
[  ]	Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
[  ]	Definitive Information Statement

 

	Nano Mobile Healthcare, Inc.
	(Name of Registrant As Specified In Its Charter)

 

Payment of Filing Fee (Check the appropriate box):

 

[X]	No fee required
[  ]	Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11
(1)	Title of each class of securities to which transaction applies:
(2)	Aggregate number of securities to which transaction applies:
(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)	Proposed maximum aggregate value of transaction:
(5)	Total fee paid:
[  ]	Fee paid previously with preliminary materials.
[  ]	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)	Amount Previously Paid:
(2)	Form, Schedule or Registration Statement No.:
(3)	Filing Party:
(4)	Date Filed:

 

 

 

Nano Mobile Healthcare, Inc.

3 Columbus Circle

New York, NY 10019

 

The following information is being provided to amend Nano Mobile Healthcare Inc.’s (the “Company”) preliminary information statement filed on January 8, 2016, or the information statement. Text that is bold and struck through in the disclosures below shows text being removed from those disclosures and text that is bold and underlined below shows text being added to those disclosures. Terms used but not otherwise defined herein have the meanings given to them in the information statement, and all references to captions and page numbers refer to captions and page numbers in the information statement, respectively, unless otherwise provided.

 

THE INFORMATION STATEMENT CONTAINS IMPORTANT ADDITIONAL INFORMATION AND THIS AMENDMENT SHOULD BE READ IN CONJUNCTION WITH THE INFORMATION STATEMENT. WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

 

1.	The fifth paragraph in the “Approval by Our Stockholders of the Amendments to our Charter to Effectuate the Capital Stock increase and the Reverse Stock Split” under the subsection heading “Approval Required” is amended in its entirety as follows:

 

On January 8 25, 2016, there were 341,699,478 398,755,933 shares of Common Stock issued and outstanding and 23,473,368 shares of Series A Convertible Preferred issued and outstanding for a total of 459,066,318 516,122,773 shares of Common Stock (on an as-converted basis) entitled to vote as a single class on the amendment to our Charter to effectuate the Capital Stock Increase and the Reverse Stock Split. On January 8 25, 2016, Stockholders holding an aggregate of 246,728,384 258,728,384 shares of Common Stock (on an as-converted basis), or approximately 53.75 50.13% of the outstanding Common Stock (on an as-converted basis), entitled to vote on the matters described herein, executed and delivered a written consent that approved the amendments to our Charter to effectuate the Capital Stock Increase and Reverse Stock Split.

 

WHERE YOU CAN FIND MORE INFORMATION

 

We are subject to the reporting requirements of the SEC. Accordingly, we are required to file reports with the SEC including annual reports, quarterly reports, current reports and other reports as required by SEC rules. All reports that we file electronically with the SEC are available for viewing free of charge over the Internet via the SEC’s EDGAR system at http://www.sec.gov. We will provide without charge to each person who receives a copy of this Information Statement, upon written or oral request, a copy of any information that is incorporated by reference in this Information Statement. Requests should be directed to Nano Mobile Healthcare, Inc., Attention: Secretary, 3 Columbus Circle, 15^th Floor, New York, NY 10019 or call (713) 973-5738. For further information about us, you may read and copy any reports, statements and other information filed by us at the SEC’s Public Reference Room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549-0102. You may obtain further information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.